Collegium Pharmaceutical Shares Plunge 6.7% After Q4 EPS, Revenue Miss
Collegium Pharmaceutical posted Q4 adjusted EPS of $2.04 versus $2.14 expected and revenue of $205.45M versus $207.07M, driving a 6.7% share decline into oversold territory. The shares trade about 17% below their 52-week high after 11 moves over 5% in the past year, underscoring elevated volatility.
1. Q4 Earnings Miss Spurs 6.7% Stock Drop
Collegium Pharmaceutical reported adjusted earnings of $2.04 per share in the fourth quarter versus $2.14 expected and revenue of $205.45 million compared to a $207.07 million forecast, prompting a 6.7% share decline and sending the stock into oversold territory.
2. Elevated Volatility and Relative Valuation
Over the past year, the shares have recorded 11 moves greater than 5% and currently trade approximately 17% below their 52-week high, highlighting sustained volatility despite an 80% gain over five years.
3. Prior Strong Quarter and Guidance Raise
In the third quarter of 2025, Collegium delivered net revenue of $209.4 million, up 31.4% year-over-year, exceeding forecasts and driving the company to raise its full-year revenue outlook to $775 million–$785 million and adjusted EBITDA projection to $460 million–$470 million.